Abacavir and ddI Linked to Increased MI Risk

In a surprising finding from the DAD Study, recent use of abacavir or ddI was associated with increased risk for myocardial infarction.

At this year’s Retrovirus Conference, investigators from the DAD Study reported an unexpected association between recent use of abacavir or ddI and increased risk for myocardial infarction (MI; ACC Mar 10 2008). Based on this finding, the FDA recently issued an “early communication,” stating that it will be investigating the safety of these two drugs. Now, the DAD results have been published in The Lancet, along with a letter from the maker of abacavir (GlaxoSmithKline [GSK]).

The DAD analysis involved 33,347 HIV-infected patients from 11 cohorts and focused on cumulative, past, and recent (within the previous 6 months) use of five NRTIs: AZT, ddI, d4T, 3TC, and abacavir. Statistical adjustments were made for cardiovascular risk factors that…

Reviewing Author

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

Abacavir and ddI Linked to Increased MI Risk

Topics

Reviewing Author